ATEC (ATEC) Q1 2024: Surgical Revenue Jumps 30% as Lateral Franchise Drives Market Share Gains
ATEC’s Q1 results underscore a business in acceleration mode, with lateral spine procedures and robust surgeon adoption fueling outperformance across both established and expansion markets. The company’s spine-only focus, investments in procedural innovation, and disciplined sales force expansion are translating into durable market share gains and margin leverage. Guidance raises and capital deployment signal confidence in sustainable, self-funding growth, but execution on international and new technology launches remains a watchpoint.
Summary
- Lateral Franchise Momentum: Leadership in lateral spine surgery is powering adoption and expansion into new geographies.
- Margin Leverage Emerges: Operating leverage and disciplined investment are moving ATEC toward breakeven and profitability inflection.
- Growth Engines Scaling: EOS informatics, Valence robotics, and international launches set the stage for multi-year revenue acceleration.
Business Overview
ATEC, or Alphatec Holdings, is a pure-play spine surgery technology company that designs, develops, and sells procedural solutions for spine disorders. The business is structured around two primary segments: surgical revenue (implant systems, procedural tools, and neuromonitoring for spine surgery) and EOS revenue (advanced imaging and informatics platform for surgical planning and alignment). ATEC generates revenue by selling implants, enabling technologies, and capital equipment to hospitals and surgeons, with a focus on U.S. and select international markets.
Performance Analysis
ATEC delivered 27% total revenue growth in Q1, with surgical revenue up 30% and EOS revenue up 5%. The surgical segment, which accounts for the majority of the business, benefited from a 23% increase in surgical volume and a 6% rise in average revenue per case, reflecting higher procedure complexity and a favorable shift toward lateral surgeries. Same-store sales in established territories rose 28%, highlighting both organic growth and successful territory expansion.
Margin expansion was evident, with adjusted EBITDA loss narrowing by 450 basis points year-over-year, driven by SG&A leverage, improved gross margin in EOS, and higher utilization of distribution infrastructure. Investments in revenue-generating assets—primarily instrument sets and inventory to support the growing sales team—continued, but management emphasized that these outlays are building a base for self-sustaining growth as the business approaches cash flow breakeven in 2025.
- Lateral Leadership Drives Volume: The lateral franchise remains the largest contributor to growth, with peer-reviewed validation and proprietary neuromonitoring as key differentiators.
- Sales Force Expansion: Strategic hiring and training resulted in a 21% increase in surgeon adoption and deeper penetration in high-opportunity U.S. markets.
- EOS Platform Progress: EOS revenue, though lapping tough comps, is positioned for future upside with the launch of the Insight informatics suite and increasing integration into procedural workflows.
ATEC’s consistent execution on both top-line growth and margin improvement positions the company for a transition from high-growth investment phase to scalable, profitable operations over the next 12-24 months.
Executive Commentary
"We are confident in the robustness of the growth as we continue to see outsized growth in especially our established territories, which was 28% growth of same-store sales. So we think that's a great statistic."
Pat Miles, Chairman and CEO
"The consistent adjusted EBITDA margin expansion that we are driving is aligning solidly with our expectations, giving us great confidence in our ability to execute the long-term profitability commitments that we detailed at the long-range plan in March."
Todd Koning, CFO
Strategic Positioning
1. Lateral Spine Franchise as Core Differentiator
ATEC’s leadership in lateral spine surgery, a technique for accessing the spine from the side, is central to its growth story. The company leverages proprietary neuromonitoring (SafeOp) and procedural know-how, resulting in clinical distinction and surgeon loyalty. With approximately 12% share in the lateral market and ongoing disruption of traditional posterior approaches, ATEC’s lateral platform is expanding its addressable market and deepening competitive moats.
2. Procedural Innovation and Technology Integration
ATEC is investing heavily in next-generation enabling technologies, including the EOS informatics platform and Valence navigation robotics. EOS automates surgical planning and alignment, while Valence aims to elevate precision in lateral procedures. These platforms are protected by extensive intellectual property and are designed to drive objectivity, predictability, and data-driven decision-making in spine surgery—a key differentiator as the market moves beyond “widget” sales to procedural solutions.
3. Sales Force and Market Coverage Expansion
The company’s disciplined approach to sales force expansion, focusing on narrow and deep market penetration, is yielding strong adoption in both mature and new territories. Strategic hiring from competitors and methodical territory development have enabled ATEC to achieve 25%+ share in its best U.S. markets, with significant white space remaining in undercovered regions.
4. International Growth Pipeline
ATEC’s international strategy is taking shape, with Australia and New Zealand serving as successful launch markets for lateral procedures. Japan represents the next major opportunity, with regulatory clearances paving the way for a phased entry starting with conventional implants and lateral techniques. The company’s methodical approach acknowledges the conservative pace of international adoption but positions ATEC for long-term replication of its U.S. growth curve abroad.
5. Capital Allocation and Asset Investment Discipline
ATEC’s deployment of capital into revenue-generating assets—primarily instrument sets— is a deliberate strategy to support rapid sales growth. Management highlights a 3x return over asset life and a shift toward self-funding growth as margin leverage accelerates. The current investment cycle is building capacity ahead of the company’s 20%+ revenue CAGR targets and anticipated inflection to positive free cash flow in 2025.
Key Considerations
ATEC’s Q1 results reflect a company executing on multiple growth levers, but the path to sustained profitability and global scale will require continued operational discipline and successful technology adoption.
Key Considerations:
- Technology Differentiation as a Moat: SafeOp neuromonitoring and EOS data integration are establishing procedural standards that competitors may struggle to replicate, providing defensible market share.
- Surgeon Adoption and Training: The 150 surgeons trained in Q1 and 21% increase in surgeon adoption signal robust demand, but ongoing education and support will be critical as complexity rises.
- Sales Force Productivity Lag: While hiring is strong, management notes a lag between onboarding and revenue impact, requiring patience and sustained investment.
- Capital Deployment vs. Cash Flow: Heavy asset investment is expected to moderate as utilization rises, but near-term free cash flow remains negative until the second half of 2025.
- International Execution Risk: Japan and other new markets offer long-term upside, but regulatory and adoption timelines are protracted, requiring methodical execution.
Risks
ATEC’s aggressive expansion and innovation agenda exposes the business to execution risk, particularly in scaling new technologies (Valence, EOS Insight) and integrating them into surgical workflows. Capital intensity remains high, and delays in surgeon adoption or regulatory approvals (especially internationally) could slow the path to breakeven. The competitive landscape is in flux, with larger incumbents and new entrants potentially responding to ATEC’s gains. Lastly, macroeconomic pressures on hospital capital spending could impact EOS and capital equipment sales cycles.
Forward Outlook
For Q2 and Q3, ATEC expects:
- Continued revenue growth near the 25% YoY pace, with both surgical and EOS segments contributing.
- Margin expansion to continue, with first half adjusted EBITDA approaching breakeven and a stronger second half.
For full-year 2024, management raised guidance:
- Total revenue of $601 million (+25%), with surgical revenue at $536 million (+27%) and EOS at $65 million.
- Adjusted EBITDA of $23 million, representing 570 basis points of margin expansion.
Management emphasized:
- Sales growth and operating leverage will drive the transition to cash flow breakeven in 2025.
- Technology launches (EOS Insight, Valence) and international market entries will be staged and methodical, with impact building over time.
Takeaways
ATEC’s Q1 execution validates its spine-focused strategy, with lateral leadership and procedural innovation translating into market share gains and margin leverage.
- Technology-Driven Adoption: SafeOp and EOS platforms are creating procedural stickiness and differentiating ATEC in a crowded spine market.
- Operating Leverage in Focus: Margin expansion and asset productivity are trending toward self-funding growth, but sustained discipline is needed as the investment cycle moderates.
- Next Leg of Growth: International launches, robotics integration, and expanded procedural indications (deformity, alignment) represent future upside, but require flawless execution and surgeon buy-in.
Conclusion
ATEC’s Q1 2024 results highlight a business that is outpacing the broader spine market on both growth and innovation, with clear signs of sustainable operating leverage emerging. The next phase will test the company’s ability to translate technology leadership and capital investment into durable, profitable scale—especially as it moves into new markets and procedural categories.
Industry Read-Through
ATEC’s accelerating growth and procedural innovation signal a shift in the spine surgery industry toward integrated, data-driven solutions and away from commoditized implants. The company’s success with lateral techniques and neuromonitoring is likely to pressure competitors to invest in procedural workflows and enabling technologies, not just hardware. Capital discipline and operating leverage are increasingly critical as scale and profitability become investor priorities across medtech. International expansion timelines and the complexity of integrating robotics and informatics into clinical practice remain industry-wide challenges, suggesting that only companies with deep procedural know-how and disciplined execution will sustain outperformance in the coming cycle.